Document is current
Any future updates will be listed below
-
Authors
Edwards, David W.
Kroepfl, Gabrielle M.
Jackson, Jacob M.
Chen, Sonja
Hudson-Price, Lisa
Srinivasa, Ganapati
Kannan, Kavya
Liu, Qianqian
Michalek, Joel E.
Keller, Charles https://orcid.org/0000-0003-2505-7487
-
Funding
Funding for this research was provided by:
National Cancer Institute (5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720, 5R01CA189299 and 1R01CA258720)
Team Megan Bugg and Maddie’s Promise Foundation
- License Information
-
More Information
Article History
Received: 11 March 2024
Accepted: 31 May 2024
First Online: 8 June 2024
Declarations
:
: The authors declare no competing interests.
: The authors have no direct competing interests. CK has sponsored research agreements with Roche-Genentech is co-founder of Tio Companies and Ex Ovo Therapeutics. Artisan Biopharma is a wholly-owned subsidiary of cc-TDI.
: All human cell lines used within this study were de-identified in compliance with HIPAA regulations. All animal experiments were performed in accordance with the National Institutes of Health guide for the care and use of laboratory animals and received Institutional Animal Care and Use Committee approval.
